#Japan #Tokyo #LVAD #HeartMate3 #Tokyo Women’s Medical University

Latest Developments in LVAD Treatments

In a pivotal move towards improving the lives of patients suffering from severe heart failure, Tokyo Women’s Medical University Hospital is convening a report meeting to discuss the latest progress in Left Ventricular Assist Device (LVAD) treatments. The event, scheduled for November 26, 2025, aims to shed light on innovative surgical techniques and the successful implementation of LVADs in historically hard-to-treat cases.

Challenges and the Need for Innovation

Severe heart failure patients often face daunting obstacles, especially those diagnosed with restrictive cardiomyopathy, which is characterized by a small left ventricle and impaired expansion. Traditional LVAD practices relying on left ventricular drainage have proven inadequate for maintaining blood circulation in these scenarios, leaving affected patients reliant on prolonged hospitalization with continuous medication until they can receive heart transplants. This limitation has underscored the urgent need for advancements in device technology and surgical approaches.

In response to these challenges, the cardiovascular surgery department at the Tokyo Women’s Medical University has harnessed the capabilities of Abbott Medical Japan's "HeartMate3". Notably, it has become the first institution in Japan to perform LVAD implantation using left atrial drainage in one child and one adult patient. These two cases represent a significant milestone in the nation’s cardiac care landscape, both patients showing remarkable progress post-surgery.

Conference Goals and Insights

The forthcoming conference is intended to educate the public and medical community about the expanded potential for treating previously deemed untreatable severe heart failure cases. With the successful application of the LVAD surgical technique, participants can expect to gain insights into the indications and target conditions that benefit from this modern treatment option.

The meeting will be led by prominent figures from the cardiovascular surgery department, including Professor Takeshi Niikawa and Lecturer Yuki Ichihara, both dedicated to advancing patient care and surgical innovation. As a result, attendees will gain valuable perspectives on the future outlook of LVAD treatments and the hope they bring to patients in dire need of effective interventions.

Conference Details

• - Date: November 26, 2025 (Wednesday)
• - Time: 1:00 PM - 2:00 PM (Doors open at 12:30 PM, please arrive 10 minutes early)
• - Location: B1F Room A, Yaei Memorial Hall, 8-1 Kavadamachi, Shinjuku, Tokyo

To participate in this pivotal conference, interested parties must confirm their attendance by November 25, 2025, by providing their company name, full name, number of attendees, and contact information via email or fax to the Public Relations Division of Tokyo Women’s Medical University.

Contact Information

• - Email: [email protected]
• - Phone: 03-3353-8112 (Ext. 30162)
• - Fax: 03-3353-6793

This meeting marks a hopeful turn for patients battling severe heart failure, signifying new horizons in cardiac therapy through cutting-edge technology and dedicated healthcare expertise. Together, we can unravel the potential of LVADs and redefine the expectations of treatment success in cardiology.



Image provided by Abbott Medical Japan.

About Abbott Medical Japan

Abbott Medical Japan is a prominent entity in medical care, known for pioneering technology in cardiac devices that transform the treatment landscape for heart patients across Japan and worldwide.